MedTrace Logo

The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

NCT04945031 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2021-06-30

No results posted yet for this study

Summary

A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Conditions

  • Cannabis

Interventions

OTHER

cannabis

This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-08
Primary Completion
2020-05-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04945031 on ClinicalTrials.gov